Status:
COMPLETED
Oligonucleotide Ligation Assay (OLA) Resistance Study
Lead Sponsor:
University of Washington
Collaborating Sponsors:
Seattle Children's Hospital
University of Nairobi
Conditions:
HIV Positive
Eligibility:
All Genders
2+ years
Phase:
NA
Brief Summary
The investigators propose to gauge improvements in the rate of durable suppression of viral replication by ART when OLA is used to guide clinical decisions at the PEPFAR Coptic Hope Center in Kenya, a...
Detailed Description
Durable suppression of HIV replication is critical to (1) improving the health of infected individuals, (2) to reducing HIV transmission to sexual partners and from mothers to their infants, and (3) t...
Eligibility Criteria
Inclusion
- Confirmed HIV infection
- \>2 years of age
- Qualifying for 1st-line ART based on Kenyan Guidelines
- Plan to reside in area for \>1 year
- Adult patient or parent of minor agrees to study and provides informed consent
Exclusion
- Received ART previously from Hope Center
- Ongoing ART
- Plan to start 2nd-line ART
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
991 Patients enrolled
Trial Details
Trial ID
NCT01898754
Start Date
May 1 2013
End Date
February 1 2017
Last Update
March 12 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Coptic Hospital
Maseno, Kenya
2
Coptic Hospital
Nairobi, Kenya